S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:MRKR

Marker Therapeutics - MRKR Stock Forecast, Price & News

$3.12
-0.41 (-11.62%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.86
$3.49
50-Day Range
$0.24
$3.12
52-Week Range
$2.20
$6.70
Volume
156,104 shs
Average Volume
32,978 shs
Market Capitalization
$26.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.25

Marker Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
59.9% Downside
$1.25 Price Target
Short Interest
Healthy
1.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.66mentions of Marker Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

940th out of 1,049 stocks

Pharmaceutical Preparations Industry

457th out of 514 stocks


MRKR stock logo

About Marker Therapeutics (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Fuel Marker Market Latest Research Report 2023-2029
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Marker Therapeutics, Inc. (MRKR)
See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Company Calendar

Last Earnings
11/10/2022
Today
1/29/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.25
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
-59.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,880,000.00
Net Margins
-515.88%
Pretax Margin
-515.89%

Debt

Sales & Book Value

Annual Sales
$1.24 million
Book Value
$5.29 per share

Miscellaneous

Free Float
6,086,000
Market Cap
$26.06 million
Optionable
Optionable
Beta
1.04

Key Executives

  • Peter L. Hoang
    President, Chief Executive Officer & Director
  • Juan F. VeraJuan F. Vera
    Director, Chief Operating & Scientific Officer
  • Tsvetelina Pencheva Hoang
    Vice President-Research & Development
  • Mythili Koneru
    Chief Medical Officer
  • Gerald Garrett
    Vice President-Clinical Operations













MRKR Stock - Frequently Asked Questions

Should I buy or sell Marker Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRKR, but not buy additional shares or sell existing shares.
View MRKR analyst ratings
or view top-rated stocks.

What is Marker Therapeutics' stock price forecast for 2023?

1 brokerages have issued 1 year price objectives for Marker Therapeutics' shares. Their MRKR share price forecasts range from $1.00 to $1.50. On average, they predict the company's share price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 59.9%.
View analysts price targets for MRKR
or view top-rated stocks among Wall Street analysts.

How have MRKR shares performed in 2023?

Marker Therapeutics' stock was trading at $0.2659 at the beginning of 2023. Since then, MRKR stock has increased by 1,072.2% and is now trading at $3.1170.
View the best growth stocks for 2023 here
.

Are investors shorting Marker Therapeutics?

Marker Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 767,400 shares, an increase of 30.8% from the December 31st total of 586,600 shares. Based on an average daily trading volume, of 298,500 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.2% of the shares of the company are sold short.
View Marker Therapeutics' Short Interest
.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our MRKR earnings forecast
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. The company earned $3.95 million during the quarter, compared to analyst estimates of $0.80 million. Marker Therapeutics had a negative net margin of 515.88% and a negative trailing twelve-month return on equity of 110.00%.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.30%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends
.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $3.12.

How much money does Marker Therapeutics make?

Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $26.06 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.

This page (NASDAQ:MRKR) was last updated on 1/29/2023 by MarketBeat.com Staff